Nucleotides News and Research

RSS

Preliminary discovery may help individualize prostate cancer screening in the future

Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach.

5 Apr 2011

Heavy beer drinkers with specific genetic variant at increased risk of non-cardia gastric cancer

Heavy beer drinkers who have a specific genetic variant in the cluster of three genes that metabolize alcohol are at significantly higher risk of developing non-cardia gastric cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

Common genetic variation linked to bladder cancer risk and telomere length

A common genetic variation links to both bladder cancer risk and to the length of protective caps found on the ends of chromosomes, scientists at The University of Texas MD Anderson Cancer Center reported today at the AACR 102nd Annual Meeting.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Clontech launches new SMARTer Ultra Low RNA Kit

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.

31 Mar 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

Study links genes with alcohol consumption among Asians

In a study of 1,721 Korean male drinkers aged 40󈞱 y in an urban population-based cohort, and another sample of 1,113 male drinkers from an independent rural cohort, information on average daily alcohol consumption was collected and DNA samples were collected for genotyping.

31 Mar 2011

Pharmasset commences PSI-7977 Phase 2b study against HCV

Pharmasset, Inc. announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C.

30 Mar 2011

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research.

28 Mar 2011

Life Technologies enters clinical trials for DNA SBT platform for analysis of Human Leukocyte Antigen system

Life Technologies Corporation today announced that it is the first life science tools provider entering clinical trials to prove the safety and effectiveness of their DNA sequence-based typing (SBT) platform for analysis of the Human Leukocyte Antigen (HLA) system. Submission for 510(k) clearance of this SBT platform will follow completion of the clinical trials, which is anticipated this summer.

21 Mar 2011

Modified mRNA raises hope for safe and effective cancer drugs

Modern gene therapies raise hopes of combating many diseases until now considered terminal. Nowadays, however, the methods are expensive and carry a risk of severe complications.

18 Mar 2011

New research: Rhodopsin pigment in Drosophila may detect temperature

New research from Mount Sinai School of Medicine has discovered that rhodopsin, a pigment of the retina that is responsible for the first events in the perception of light, may also be involved in temperature sensation. This detection had not been revealed in previous studies.

14 Mar 2011